This assay quantifies viable Limosilactobacillus reuteri in probiotic powders, highlighting quality control effectiveness and innovative inhibition strategies.
Accurate enumeration of viable probiotic cells in commercial products is essential for quality control, label compliance, and product development. Conventional plate counting is labour-intensive and primarily quantifies culturable cells, whereas quantitative PCR (qPCR) is rapid, strain-specific, and detects DNA from both live and dead cells. We developed and validated a strain-specific propidium monoazide (PMA)-qPCR assay targeting a unique genomic region of Limosilactobacillus reuteri IDCC 3701 (RE), an industrial probiotic strain used in multi-strain products. The assay was evaluated in pure and mixed cultures and in single- and four-strain freeze-dried probiotic powders, using calibration curves generated directly from the RE freeze-dried powder to reduce matrix mismatch. PMAxx dye treatment effectively suppressed amplification of dead-cell DNA (99.985% inhibition) with minimal impact on viable-cell amplification. The assay enabled strain-specific quantification of viable RE in cultures from 10 4 –10 9 CFU/mL, and powder-based quantification was performed within a validated linear range of ≥10 5 CFU/mL. This approach provides a practical tool for RE-containing probiotic quality control and a useful framework for extending powder-calibrated PMA-qPCR to other industrial strains.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: